phrykt

Pulmonx Corp (LUNG): who owns it and who trades it

As of Nov 16, 2026, LUNG insiders reported 55 open-market sales worth $548K and no purchases in the last 12 months, with 8% of the sale value made under pre-set 10b5-1 plans. The largest seller was Glendon E. French III (CEO), with $292K. 4 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Pulmonx

From the latest filings

Overall: more selling than buying. Insiders mostly sold. Funds and famous investors were close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns LUNG

108 funds and institutions reported LUNG shares worth $34.1M at the end of Q2 2026, about 62% of the company. The largest holder is Primecap Management Co with 10.9%.

Funds and institutions (13F) 62%Everyone else 38%

10 largest owners, by share of the company

Primecap Management Co10.9%
Morgan Stanley6.9%
Soleus Capital Management, L.P.6.6%
Vanguard Capital Management LLC3.9%
ExodusPoint Capital Management, LP2.9%
Almitas Capital LLC2.5%
BlackRock, Inc.2.1%
Stonepine Capital Management, LLC1.9%
Jane Street Group, LLC1.8%
Braidwell LP1.8%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Primecap Management Co4.61M10.92%$6M-2%
Morgan Stanley2.92M6.92%$3.8M-27%
Soleus Capital Management, L.P.2.79M6.60%$3.6MNo change
Vanguard Capital Management LLC1.63M3.86%$2.1M-0%
ExodusPoint Capital Management, LP1.22M2.90%$1.6M-37%
Almitas Capital LLC1.06M2.52%$1.4M–
BlackRock, Inc.882,4902.09%$1.1M-67%
Stonepine Capital Management, LLC815,4361.93%$1.1M+6%
Jane Street Group, LLC758,2311.80%$986K+469%
Braidwell LP752,5411.78%$978KNo change
AQR Capital Management LLC744,9631.76%$968K+108%
Parkman Healthcare Partners LLC646,5641.53%$841K-14%
Geode Capital Management, LLC452,6841.07%$589K-52%
Renaissance Technologies LLC425,1101.01%$553K+33%
ADAR1 Capital Management, LLC404,4970.96%$526K+8%
Deutsche Bank Ag\402,3160.95%$523K-65%
D. E. Shaw & Co., Inc.327,5280.78%$426K-2%
Jefferies Financial Group Inc.285,1100.68%$371KNo change
Cfm Wealth Partners LLC264,0390.63%$343KNo change
Vanguard Fiduciary Trust Co250,5110.59%$326K-11%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, LUNG insiders reported $0 of open-market purchases and $548K of sales. 8% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$548K
55 trades, 5 people
Sales under a 10b5-1 plan
8%
Share of sale value
Latest trade
Sep 1, 2026
Filed Sep 3, 2026

Purchases and sales by month

$177K$177KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Sep 1, 2026Glendon E. French IIICEOSale4,098$2.26$9.3KForm 4
Sep 1, 2026Glendon E. French IIICEOSale37,784$2.26$85.4KForm 4
Sep 1, 2026Srikanth RadhakrishnanChief Science & Techn. OSale2,643$2.26$6KForm 4
Sep 1, 2026Srikanth RadhakrishnanChief Science & Techn. OSale5,863$2.26$13.3KForm 4
Sep 1, 2026Srikanth RadhakrishnanChief Science & Techn. OSale3,618$2.26$8.2KForm 4
Sep 1, 2026Srikanth RadhakrishnanChief Science & Techn. OSale2,121$2.26$4.8KForm 4
Sep 1, 2026David Aaron LehmanGeneral CounselSale3,807$2.26$8.6KForm 4
Sep 1, 2026David Aaron LehmanGeneral CounselSale4,827$2.26$10.9KForm 4
Sep 1, 2026David Aaron LehmanGeneral CounselSale3,476$2.26$7.9KForm 4
Sep 1, 2026David Aaron LehmanGeneral CounselSale2,224$2.26$5KForm 4
Sep 1, 2026Geoffrey Beran RoseChief Commercial OfficerSale2,213$2.26$5KForm 4
Sep 1, 2026Geoffrey Beran RoseChief Commercial OfficerSale1,530$2.26$3.5KForm 4
Sep 1, 2026Geoffrey Beran RoseChief Commercial OfficerSale1,746$2.26$3.9KForm 4
Sep 1, 2026Geoffrey Beran RoseChief Commercial OfficerSale2,390$2.26$5.4KForm 4
Jun 2, 2026Glendon E. French IIICEOSale13,511$1.57$21.2KForm 4
Jun 1, 2026Srikanth RadhakrishnanChief Science &Techn. OfSale3,684$1.54$5.7KForm 4
Jun 1, 2026Srikanth RadhakrishnanChief Science &Techn. OfSale5,969$1.54$9.2KForm 4
Jun 1, 2026Srikanth RadhakrishnanChief Science &Techn. OfSale2,691$1.54$4.1KForm 4
Jun 1, 2026Srikanth RadhakrishnanChief Science &Techn. OfSale2,153$1.54$3.3KForm 4
Jun 1, 2026David Aaron LehmanGENERAL COUNSELSale3,539$1.54$5.5KForm 4
Jun 1, 2026David Aaron LehmanGENERAL COUNSELSale4,915$1.54$7.6KForm 4
Jun 1, 2026David Aaron LehmanGENERAL COUNSELSale3,876$1.54$6KForm 4
Jun 1, 2026David Aaron LehmanGENERAL COUNSELSale2,264$1.54$3.5KForm 4
Jun 1, 2026Geoffrey Beran RoseCHIEF COMMERCIAL OFFICERSale1,557$1.54$2.4KForm 4
Jun 1, 2026Geoffrey Beran RoseCHIEF COMMERCIAL OFFICERSale1,778$1.54$2.7KForm 4
Jun 1, 2026Geoffrey Beran RoseCHIEF COMMERCIAL OFFICERSale2,254$1.54$3.5KForm 4
Jun 1, 2026Geoffrey Beran RoseCHIEF COMMERCIAL OFFICERSale2,434$1.54$3.7KForm 4
Jun 1, 2026Glendon E. French IIICEOSale4,171$1.54$6.4KForm 4
Jun 1, 2026Glendon E. French IIICEOSale38,467$1.54$59.2KForm 4
Mar 2, 2026Srikanth RadhakrishnanChief Science &Techn. OfSale4,198$1.43$6KForm 4
Mar 2, 2026Srikanth RadhakrishnanChief Science &Techn. OfSale2,461$1.43$3.5KForm 4
Mar 2, 2026Srikanth RadhakrishnanChief Science &Techn. OfSale756$1.43$1.1KForm 4
Mar 2, 2026Srikanth RadhakrishnanChief Science &Techn. OfSale3,068$1.43$4.4KForm 4
Mar 2, 2026Glendon E. French IIICEOSale58,368$1.43$83.5KForm 4
Mar 2, 2026Glendon E. French IIICEOSale2,708$1.43$3.9KForm 4
Mar 2, 2026Glendon E. French IIICEOSale6,737$1.43$9.6KForm 4
Mar 2, 2026Geoffrey Beran RoseCHIEF COMMERCIAL OFFICERSale2,911$1.43$4.2KForm 4
Mar 2, 2026Geoffrey Beran RoseCHIEF COMMERCIAL OFFICERSale2,125$1.43$3KForm 4
Mar 2, 2026Geoffrey Beran RoseCHIEF COMMERCIAL OFFICERSale835$1.43$1.2KForm 4
Mar 2, 2026Geoffrey Beran RoseCHIEF COMMERCIAL OFFICERSale1,861$1.43$2.7KForm 4
Mar 2, 2026David Aaron LehmanGENERAL COUNSELSale1,163$1.43$1.7KForm 4
Mar 2, 2026David Aaron LehmanGENERAL COUNSELSale4,433$1.43$6.3KForm 4
Mar 2, 2026David Aaron LehmanGENERAL COUNSELSale4,051$1.43$5.8KForm 4
Mar 2, 2026David Aaron LehmanGENERAL COUNSELSale2,590$1.43$3.7KForm 4
Dec 8, 2025Daniel P FlorinDirectorSale plan23,321$1.99$46.4KForm 4
Dec 1, 2025Glendon E. French IIICEOSale2,524$1.57$4KForm 4
Dec 1, 2025Glendon E. French IIICEOSale6,281$1.57$9.9KForm 4
Dec 1, 2025Geoffrey Beran RoseCHIEF COMMERCIAL OFFICERSale1,522$1.57$2.4KForm 4
Dec 1, 2025Geoffrey Beran RoseCHIEF COMMERCIAL OFFICERSale1,738$1.57$2.7KForm 4
Dec 1, 2025Geoffrey Beran RoseCHIEF COMMERCIAL OFFICERSale683$1.57$1.1KForm 4
Dec 1, 2025Geoffrey Beran RoseCHIEF COMMERCIAL OFFICERSale2,379$1.57$3.7KForm 4
Dec 1, 2025David Aaron LehmanGENERAL COUNSELSale2,176$1.57$3.4KForm 4
Dec 1, 2025David Aaron LehmanGENERAL COUNSELSale3,725$1.57$5.8KForm 4
Dec 1, 2025David Aaron LehmanGENERAL COUNSELSale976$1.57$1.5KForm 4
Dec 1, 2025David Aaron LehmanGENERAL COUNSELSale3,401$1.57$5.3KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Glendon E. French IIIPresident and CEO, Director–$292KSep 1, 2026
David Aaron LehmanGENERAL COUNSEL–$88.5KSep 1, 2026
Srikanth RadhakrishnanChief Science &Techn. Officer–$69.5KSep 1, 2026
Geoffrey Beran RoseCHIEF COMMERCIAL OFFICER–$51.1KSep 1, 2026
Daniel P FlorinDirector–$46.4KDec 8, 2025
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

LUNG short interest

Low short interest. 1.8% of LUNG shares are sold short: about 1 share in 55. Over the last 12 reports the number of shares short went down 71%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 787,512 LUNG shares were sold short, 1.8% of the shares outstanding, up 12.7% from the report before. At the average daily volume of 1.60M shares, buying them all back would take about 1.0 trading days (days to cover).

Shares short, % of all shares

1.81%May 15Oct 307.43%

Days to cover

1.0May 15Oct 308.1

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 2026787,5121.81%+13%1.60M1.0
Oct 15, 2026698,6441.63%-13%274,7052.5
Sep 30, 2026802,7331.87%-5%251,0083.2
Sep 15, 2026847,8421.97%-13%337,3012.5
Aug 31, 2026976,2372.27%-8%377,8442.6
Aug 14, 20261.07M2.48%+1%900,6471.2
Jul 31, 20261.06M2.47%+0%730,6171.4
Jul 15, 20261.06M2.50%-8%227,5424.6
Jun 30, 20261.15M2.72%-49%862,5931.3
Jun 15, 20262.26M5.36%-20%314,1517.2
May 29, 20262.82M6.67%+4%417,1286.8
May 15, 20262.70M6.39%-24%567,0044.8

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Pulmonx company events

Pulmonx filed 6 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Oct 27, 2026.

  1. Oct 27, 2026ResultsReleased financial results. Filing
  2. Jul 29, 2026ResultsReleased financial results. Filing
  3. Jun 4, 2026VoteReported shareholder vote results. Filing
  4. Apr 29, 2026ResultsReleased financial results. Filing
  5. Mar 5, 2026AgreementPulmonx Corporation entered into a Credit Agreement and Guaranty and a Security Agreement, with Perceptive Credit Holdings V, LP, as the initial lender, administrative agent and collateral agent. Filing
  6. Mar 4, 2026ResultsReleased financial results. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Pulmonx financials

Famous investors that hold LUNG

4 of the 50 well-known investors we track reported holding LUNG in their latest 13F filing. The largest position is Jim Simons's, worth $1M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Jim Simons · Renaissance TechnologiesQ3 2026530,336$1M0.0%+25%
Israel Englander · Millennium ManagementQ3 2026179,957$344K0.0%-14%
Ken Griffin · Citadel AdvisorsQ3 202661,120$117K0.0%-57%
Steve Cohen · Point72 Asset ManagementQ3 202610,067$19.2K0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named LUNG in the last 120 days.

FiledHolderFormStake
Nov 5, 2026PRIMECAP MANAGEMENT CO/CA/13G/A10.3%
Nov 5, 2026PRIMECAP MANAGEMENT CO/CA/13G/A10.3%

Questions about Pulmonx Corp (LUNG) stock

Who owns the most LUNG stock?

The largest reported owner of Pulmonx Corp (LUNG) is Primecap Management Co, with 10.9% of the company. In total, 108 funds and institutions reported holding LUNG at the end of Q2 2026, together about 62% of the shares. See the largest owners.

Are LUNG insiders buying or selling?

In the last 12 months, LUNG insiders reported no open-market purchases and 55 sales worth $548K. The latest trade was on Sep 1, 2026. See every trade.

What is the short interest in LUNG?

As of Oct 30, 2026, 787,512 LUNG shares were sold short, 1.8% of the shares outstanding, up 12.7% from the report before. At the average daily volume of 1.60M shares, buying them all back would take about 1.0 trading days (days to cover). See the history.

Which famous investors hold LUNG?

4 of the 50 well-known investors we track reported LUNG in their latest 13F filing, including Jim Simons, Israel Englander, Ken Griffin. The largest position is worth $1M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.